Result of AGM

ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2016

Results of Annual General Meeting held on 29 April 2016

AstraZeneca PLC announced the results of the voting at its Annual General Meeting today.  As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 11 were passed as special resolutions.

RESOLUTION VOTES   FOR %   OF VOTES CAST VOTES   AGAINST %   OF VOTES CAST VOTES   CAST IN TOTAL TOTAL   VOTES CAST AS A % OF ISSUED SHARE CAPITAL VOTES   WITHHELD
1 To   receive the Company's Accounts and the Reports of the Directors and Auditor   for the year ended 31 December 2015 924,514,473 99.61 3,665,459 0.39 928,179,932 73.40% 8,998,621
2 To   confirm dividends 933,191,043 99.69 2,915,972 0.31 936,107,015 74.03% 1,071,537
3 To   re-appoint KPMG LLP, London as Auditor 929,918,594 99.56 4,151,154 0.44 934,069,748 73.87% 3,108,804
4 To   authorise the Directors to agree the remuneration of the Auditor 934,984,319 99.89 988,556 0.11 935,972,875 74.02% 1,204,865
5a To   re-elect Leif Johansson as a Director 861,678,834 94.69 48,321,545 5.31 910,000,379 71.96% 27,177,942
5b To   re-elect Pascal Soriot as a Director 935,167,473 99.93 697,471 0.07 935,864,944 74.01% 1,342,796
5c To   re-elect Marc Dunoyer as a Director 931,875,086 99.58 3,920,615 0.42 935,795,701 74.00% 1,380,982
5d To   re-elect Cori Bargmann as a Director 935,157,654 99.93 635,873 0.07 935,793,527 74.00% 1,384,110
5e To   re-elect Geneviève Berger as a Director 935,199,102 99.93 622,099 0.07 935,821,201 74.00% 1,356,436
5f To   re-elect Bruce Burlington as a Director 933,026,505 99.70 2,762,355 0.30 935,788,860 74.00% 1,389,088
5g To   re-elect Ann Cairns as a Director 933,220,149 99.72 2,618,183 0.28 935,838,332 74.01% 1,339,989
5h To   re-elect Graham Chipchase as a Director 919,686,570 98.97 9,526,012 1.03 929,212,582 73.48% 7,965,366
5i To   re-elect Jean-Philippe Courtois as a Director 933,177,891 99.72 2,593,420 0.28 935,771,311 74.00% 1,406,637
5j To   re-elect Rudy Markham as a Director 923,984,532 98.74 11,766,347 1.26 935,750,879 74.00% 1,427,442
5k To   re-elect Shriti Vadera as a Director 927,479,182 99.11 8,287,726 0.89 935,766,908 74.00% 1,410,552
5l To   re-elect Marcus Wallenberg as a Director 870,828,312 95.76 38,511,577 4.24 909,339,889 71.91% 27,837,158
6 To   approve the Annual Report on Remuneration for the year ended 31 December 2015 836,396,151 89.61 96,959,428 10.39 933,355,579 73.81% 3,822,290
7 To   authorise limited EU political donations 908,106,542 97.83 20,185,176 2.17 928,291,718 73.41% 8,886,009
8 To   authorise the Directors to allot shares 849,809,843 90.97 84,303,774 9.03 934,113,617 73.87% 3,064,122
9 To   authorise the Directors to disapply pre-emption rights 922,425,478 98.82 11,009,374 1.18 933,434,852 73.82% 3,742,888
10 To   authorise the Company to purchase its own shares 926,166,577 98.96 9,722,078 1.04 935,888,655 74.01% 1,289,613
11 To   reduce the notice period for general meetings 829,946,353 88.85 104,116,202 11.15 934,062,555 73.87% 3,115,081

 

 

Issued capital

As at 27 April 2016, the number of issued shares of the Company was 1,264,542,488 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM.  In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

A C N Kemp

Company Secretary

29 April 2016

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links